Illumina has announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a coho...
QIAGEN has announced that its QIAsprint Connect and QIAseq FX DNA Library Kit will support automated DNA extraction and ...
CellProthera, a clinical-stage company developing regenerative cell therapies for ischemic diseases, has announced its s...
Japan-based pharma firm Shionogi has announced that Shionogi China, a Shionogi group company in China, has entered into ...
DKSH has signed an agreement to acquire 100% of NewBridge Pharmaceuticals, a Dubai-headquartered healthcare commercialis...
US-based BioMarin Pharmaceutical Inc. has entered into an exclusive worldwide license agreement with South Korea-based G...
Australia-based Firebrick Pharma has announced the launch of its third product in the Nasodine range: Nas...
Japan-based Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately JPY 1.06 b...
SG Austria/Austrianova, the group comprising Austrianova Singapore, Austrianova Thailand and Anovade UG, has announced t...
SG Austria/Austrianova, the group comprising Austrianova Singapore, Austrianova Thailand and Anovade UG, has announced t...
In 2026, Novo Nordisk’s Awiqli became the first once-weekly basal insulin to receive approval from the US Food and...
American multinational pharmaceutical company Merck (Known as Merck Sharp & Dohme or MSD outside the United States a...
If Day 1 of BIX 2026 asked what makes a Korean asset partnerable, Day 2 asked what happens once someone wants it. Thursd...
Japan-based Astellas Pharma Inc. has entered into an exclusive option and license agreement for DAX-044, Audax’s l...
PeptiDream Inc., a public biopharmaceutical company based in Kawasaki, Japan, focused on the discovery and development o...
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and Novartis ha...
BIOPLUS-INTERPHEX KOREA 2026 opened at COEX in Seoul on Wednesday with a first day that made its priorities plain. Hoste...
US-based Gilead Sciences, Inc. has entered into a definitive agreement to acquire an oral IL-23R inhibitor programme, in...
HighTide Therapeutics, Inc., an innovative biopharmaceutical company specializing in the development of multifunctional,...
Singapore’s biopharmaceutical industry has launched a S$4.8 million study award to strengthen its manufacturing ta...
Kaigene, Inc., a US-based biotechnology company developing antibody medicines for autoimmune diseases, has announced an ...
AI Proteins, Inc., a US-based biotechnology company that utilises computational de novo protein design to create therape...
Researchers at the National University of Singapore (NUS) have identified how a stiffer ovarian environment can disrupt ...
Samsung Biologics reported third-quarter revenue of KRW 1.49 trillion and operating profit of KRW 640 billion, supported...
Shionogi and F2G have reported detailed results from the global Phase 3 OASIS study evaluating investigational oral anti...
